Table 2 in Polyketide-derived macrobrevins from marine macroalga-associated Bacillus amyloliquefaciens as promising antibacterial agents against pathogens causing nosocomial infections

Table 2 Antibacterial activities of macrobrevin analogues 1–4 and commercial standards against clinical pathogens.
Pathogens1234ChloramphenicolAmpicillinE. coli (MTCC 443)17b ± 0.05 (6.25)23 a ± 0.01 (3.12)29 a ± 0.05 (3.12)24 a ± 0.10 (6.25)16b ± 0.02 (6.25)10 c ± 0.02 (6.25)V. parahaemolyticus (MTCC 451)21b ± 0.34 (3.12)26 a ± 0.05 (1.56)33 a ± 0.15 (1.56)26 a ± 0.05 (3.12)11 c ± 0.06 (6.25)12 c ± 0.01 (6.25)P. aeruginosa (ATCC 27853)19b ± 0.03 (3.12)13c ± 0.20 (6.25)23a ± 0.25 (1.56)22b ± 0.02 (3.12)11c ± 0.02 (12.50)11c ± 0.04 (12.50)K. pneumoniae (ATCC 13883)11c ± 0.04 (6.25)16b ± 0.05 (6.25)25a ± 0.02 (1.56)24a ± 0.06 (3.12)7 d ± 0.04 (12.50)9d ± 0.04 (12.50)E. tarda (MTCC 2400)20b ± 0.02 (6.25)25 a ± 0.05 (3.12)27 a ± 0.03 (3.12)27 a ± 0.05 (3.12)14 c ± 0.01 (6.25)13 c ± 0.01 (6.25)S. pyogenes (MTCC, 1924)22b ± 0.01 (3.12)21b ± 0.02 (3.12)30 a ± 0.01 (1.56)23 a ± 0.02 (6.25)15 c ± 0.03 (6.25)15 c ± 0.05 (6.25)MRSA (ATCC 33592)20b ± 0.15 (6.25)22b ± 0.01 (3.12)24 a ± 0.10 (1.56)21b ± 0.01 (3.12)14 c ± 0.02 (6.25)14 c ± 0.02 (12.50)VRE fs (ATCC 51299)22b ± 0.20 (6.25)24 a ± 0.04 (6.25)34 a ± 0.05 (1.56)25 a ± 0.05 (6.25)8d ± 0.01 (6.25)11 c ± 0.05 (6.25)